Share Price | Olema Pharmaceuticals, Inc. Stock Analysis & Recommendation

Q: What does Olema Pharmaceuticals, Inc. do?

Overview: Olema Pharmaceuticals, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot: Net Profit: -30 Million (Quarterly Results - Mar 2025) Market Cap: USD 274.37 Million (Micro Cap)Key Metrics: P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -1.02 Return on Equity: -33.61% Price to Book: 0.72Contact Details: Details: No Company Details Available Registrar Address: Not available.

Q: Is Olema Pharmaceuticals, Inc. technically bullish or bearish?

As of 11 September 2025, the technical trend for Olema Pharmaceuticals, Inc. has changed from sideways to bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. However, the weekly RSI is bearish, suggesting some short-term weakness. The daily moving averages are bullish, reinforcing the overall positive trend. The KST shows a bullish weekly signal but is bearish monthly, which presents a mixed picture. Dow Theory indicates a mildly bullish stance on both weekly and monthly time frames. The Bollinger Bands are bullish weekly but sideways monthly, adding to the mixed signals.In terms of performance, Olema Pharmaceuticals has outperformed the S&P 500 significantly over the past week (6.37% vs. 1.05%) and month (47.74% vs. 2.33%), while it has underperformed over the past year (-33.57% vs. 17.14%). Overall, the current technical stance is bullish, albeit with some short-term bearish indicators.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

426.4 k

Shareholding (Sep 2025)

FII

13.50%

Held by 82 FIIs

DII

46.55%

Held by 30 DIIs

Promoter

19.51%

How big is Olema Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Olema Pharmaceuticals, Inc. has a market capitalization of 274.37 million and reported net sales of 0.00 million with a net profit of -128.89 million over the latest four quarters. Shareholder's funds are at 408.96 million and total assets at 556.07 million.

View full answer

What does Olema Pharmaceuticals, Inc. do?

22-Jun-2025

Olema Pharmaceuticals, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $30 million and a market cap of $274.37 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.02.

View full answer

Is Olema Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 11, 2025, Olema Pharmaceuticals shows a bullish technical trend with strong weekly performance, despite some short-term bearish indicators, having outperformed the S&P 500 recently while underperforming over the past year.

View full answer

Compare Olema Pharmaceuticals, Inc. with Similar Stocks

Harrow, Inc.Evolus, Inc.Repare Therapeutics, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 2,068 Million ()

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-1.06

Return on Equity

-48.77%

Price to Book

6.73

Revenue and Profits:

Net Sales:

(Quarterly Results - Sep 2025)

Net Profit:

-42 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

465.84%

6 Months

159.44%

1 Year

84.44%

2 Years

219.82%

3 Years

480.95%

4 Years

-15.79%

5 Years

0.0%

Olema Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-195.73%

EBIT to Interest (avg)

-96.21

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-1.02

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.80

EV to EBIT

0.61

EV to EBITDA

0.61

EV to Capital Employed

10.51

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

1735.02%

ROE (Latest)

-33.61%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Bullish

RSI

Bearish

No Signal

Bollinger Bands

Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Majority shareholders

Domestic Funds

Held in 40 Schemes (20.38%)

Foreign Institutions

Held by 82 Foreign Institutions (13.5%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Sep 2025 is -21.97% vs -60.93% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-45.80",
          "val2": "-37.50",
          "chgp": "-22.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-42.20",
          "val2": "-34.60",
          "chgp": "-21.97%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -33.92% vs 7.73% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.90",
          "val2": "-104.60",
          "chgp": "-35.66%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-129.50",
          "val2": "-96.70",
          "chgp": "-33.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Sep'25

Sep'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-45.80

-37.50

-22.13%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-42.20

-34.60

-21.97%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Sep 2025 is 0.00% vs 0.00% in Sep 2024

Consolidated Net Profit

YoY Growth in quarter ended Sep 2025 is -21.97% vs -60.93% in Sep 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-141.90

-104.60

-35.66%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-129.50

-96.70

-33.92%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -33.92% vs 7.73% in Dec 2023

All Annual Results

Company CV

About Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available

Olema Pharmaceuticals, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Olema Pharmaceuticals, Inc.?

Watch in Real-Time

What does Olema Pharmaceuticals, Inc. do?

Is Olema Pharmaceuticals, Inc. technically bullish or bearish?

Compare Olema Pharmaceuticals, Inc. with Similar Stocks

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Sep 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Sep'25 - YoY

Annual Results Snapshot (Consolidated) - Dec'24

About Olema Pharmaceuticals, Inc.

Company Coordinates